Modality
Degrader
MOA
CDK2i
Target
CDK4/6
Pathway
Neuroinflam
FLGIST
Development Pipeline
Preclinical
~Jul 2018
→ ~Oct 2019
Phase 1
Jan 2020
→ May 2031
Phase 1Current
NCT08836612
1,363 pts·FL
2024-09→2029-08·Recruiting
NCT03623047
773 pts·FL
2020-01→2031-05·Active
2,136 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-08-155mo awayNDA· GIST
2029-08-133.4y awayInterim· FL
2031-05-195.1y awayInterim· FL
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1
Active
P1
Recruit…
Catalysts
NDA
2026-08-15 · 5mo away
GIST
Interim
2029-08-13 · 3.4y away
FL
Interim
2031-05-19 · 5.1y away
FL
RecruitingActive|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 |